EGTX — Egetis Therapeutics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK2.11bn
- SEK1.97bn
- SEK62.40m
Brief: PledPharma: Results From Prematurely Closed PledOx POLAR Program
Brief: Finansinspektionen Says Fjärde AP-Fonden Increases Stake In PledPharma To 8.67%
Brief: PledPharma: FDA Grants Rare Pediatric Disease Designation To Emcitate
Brief: PledPharma Q3 Loss Narrows To SEK 24.7 Mln
Brief: Pledpharma To Acquire Rare Thyroid Therapeutics
Brief: PledPharma Q2 Net Loss Widens To SEK 36.2 Million
Brief: Pledpharma To Initiate One Pivotal Phase II/III Study With Aladote
Brief: PledPharma Presents Results From Study On Aladote For Paracetamol Poisoning
Brief: Pledpharma Prepares For Listing On Nasdaq Stockholm Main Market In 2019
Brief: Pledpharma July-September Quarterly Result At SEK 18.8 Mln
Brief: Pledpharma: Positive Results From The Aladote PoP Study
Brief: Pledpharma April-June Revenue at SEK 9.7 mln
Brief: PledPharma: Aladote Concluded As Safe In First Clinical Study
Brief: PledPharma Q1 Result At Loss SEK 15.8 Mln
Brief: PledPharma Gets Approval Letter From European Patent Office
Brief: PledPharma Q4 Net Loss Widens To SEK 32.1 Million
Brief: PledPharma Updates On Pledox Phase I Study In Japan
Brief: PledPharma: Aladote Presented At Pharmacology Conference
Brief: Pledpharma and Solasia enter license agreement on Pledox in Asia